What is Biosceptre?
Biosceptre is a biotechnology innovator specializing in the development of targeted therapeutics designed to address the limitations of current cancer treatments. At the core of its technological portfolio is the BRiDGECAR system, a pioneering universal CAR T platform. Unlike traditional single-target therapies, the BRiDGECAR system integrates nfP2X-targeted CAR T cells with a diverse array of antibodies, providing a modular and scalable approach to oncology. This mechanism is engineered to enhance the efficacy and reach of immunotherapy, potentially offering a universal solution for a wide spectrum of cancer types. By focusing on the nfP2X receptor, Biosceptre aims to unlock new pathways for immune-mediated tumor destruction, positioning itself as a critical player in the global effort to improve patient outcomes in oncology.
How much funding has Biosceptre raised?
Biosceptre has raised a total of $16.4M across 3 funding rounds:
Unspecified
$4.7M
Private Equity
$671K
Series A
$10.7M
Unspecified (2014): $4.7M, investors not publicly disclosed
Private Equity (2015): $671K, investors not publicly disclosed
Series A (2017): $10.7M supported by Tuspark Science and Technology Service Group
Key Investors in Biosceptre
Tuspark Science and Technology Service Group
A large-scale integrated enterprise originating from Tsinghua University, specializing in the management of science parks and the strategic incubation of high-growth technology and biotech firms.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Biosceptre?
With the recent infusion of capital, Biosceptre is well-positioned to accelerate its clinical development pipeline and expand the reach of its BRiDGECAR technology. The strategic focus will likely center on scaling manufacturing capabilities for its CAR T systems and advancing its lead candidates through rigorous clinical trials. As the company moves into its next phase of growth, the emphasis will remain on validating the safety and efficacy of its multi-targeted approach in human subjects. Furthermore, the firm is expected to leverage its existing partnerships to navigate the complex regulatory landscape of cell therapy, ensuring that its innovative treatments can reach the market efficiently. The ongoing commitment to research and development will be pivotal in maintaining a competitive edge in the rapidly evolving landscape of immuno-oncology, where precision and versatility are the primary drivers of long-term value creation.
See full Biosceptre company page
